Showing results (1001-1010 of 1,194) with videos related to

Sort By:
Pageof 120
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
JMIR Research Protocols|March 19, 2025
Methadone Patient Access to Collaborative Treatment: Protocol for a Pilot and a Randomized Controlled Trial to Establish Feasibility of Adoption and Impact on Methadone Treatment Delivery and Patient OutcomesBeth E Meyerson, Alissa Davis, Richard A Crosby, et al.
Blood|February 7, 2008
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemiaMarc M Loriaux, Ross L Levine, Jeffrey W Tyner, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Journal of Visualized Experiments : Jove|December 14, 2011
Determination of molecular structures of HIV envelope glycoproteins using cryo-electron tomography and automated sub-tomogram averagingJoel R Meyerson, Tommi A White, Donald Bliss, et al.
The Journal of Clinical Investigation|March 5, 2014
SOX2 and p63 colocalize at genetic loci in squamous cell carcinomasHideo Watanabe, Qiuping Ma, Shouyong Peng, et al.
Nature|October 17, 2008
Activating mutations in ALK provide a therapeutic target in neuroblastomaRani E George, Takaomi Sanda, Megan Hanna, et al.
Bioorganic & Medicinal Chemistry|December 21, 2022
Discovery and characterization of orally bioavailable 4-chloro-6-fluoroisophthalamides as covalent PPARG inverse-agonistsDouglas L Orsi, Steven J Ferrara, Stephan Siegel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East AfricaWalter O Mwanda, Jackson Orem, Pingfu Fu, et al.
Pageof 120